Term
| Drug of choice in treating patients with "pure" mania |
|
Definition
|
|
Term
|
Definition
| nature of action is uncertain, appears to alter cation transport across cell membreane, influences serotonin and NE |
|
|
Term
| adverse effects of lithum |
|
Definition
| tremors, polydipsia, polyuria, Nausea, diarrhea, wt gain, decreased memory, confusion, HYPOthyroidism, transient leukocytosis and teratogen risk |
|
|
Term
| valproate (Depakote-not used as much now) |
|
Definition
| MOA unknown, may cause increased GABA availability to neurons of the brain, may mimic action of GABA at postsynaptic receptor sites |
|
|
Term
| effective in patients who rapid cycle, mixed episodes and schizoaffective, used in seizure control, and head injuries |
|
Definition
|
|
Term
| adverse effects of Valproate (depakote) |
|
Definition
| Nausea, tremors, wt gain, lethargy, hair loss, benign increase in liver function tests; rare; hepatotoxicity, agranulocytosis |
|
|
Term
|
Definition
| MOA not understood, effects may be due to stabilizations of NA channels on neurons |
|
|
Term
| used to treat seizure disorders and trigeminal neuralgia, used in schizo disorders, has properties of muscle relaxants, antidiuretic, antiarrhythmic and anticholinergics as well as TCA-imipramine |
|
Definition
|
|
Term
| adverse effects of Tegretol (carbamezapine) |
|
Definition
| nausea, sedation, dizziness, elevated liver function tests; Rare: agranulocytosis, aplastic anemia |
|
|
Term
| Trileptal (oxcarbazepine) |
|
Definition
| unk MOA, stabilizes neural membranes and inhibits repetitive firing, decreases synaptic impulse propagation |
|
|
Term
| used in partial seizures and bipolar |
|
Definition
| Trileptal (oxcarbazepine) |
|
|
Term
| adverse reactions of Trileptal (oxcarbazepine) |
|
Definition
| hyponatremia, thrombocytopenia, steven-johnson syndrome, leucopenia, dizziness, somnolence, diplopia, fatigue, nausea, confusion and nervousness |
|
|
Term
|
Definition
| acts on NA channels to stabilize neuronal membranes, therefore inhibiting transmitter release of glutamate |
|
|
Term
| used for adjunctive treatment of partial seizures in adults with epilepsy, no problems with WT gain, tremors or memory deficit, may be effective as antidepressant |
|
Definition
|
|
Term
| adverse effects of Lamictal (lamotrigine) |
|
Definition
| N/V, dizziness, ataxia, blurred vision, skin rash, SEVERE steven-johnson syndrome |
|
|
Term
| treats nightmares or dreams may become more vivid (PTSD) |
|
Definition
|
|
Term
|
Definition
| Trileptal (oxycarbazepine),Lamictal (lamotrigine)*severe,* |
|
|
Term
| less weight gain problems |
|
Definition
|
|
Term
| Labs for Lamictal (lamotrigine) |
|
Definition
|
|
Term
| Labs for Trileptal (oxycarbazepine) |
|
Definition
|
|
Term
| Labs for Tegretol (carbamezapine) |
|
Definition
| CBC with electrolytes Q 2 weeks for two months and then quarterly; LFTs and renal function after 1 month Q 3 months for first year and then annually; (6-12 ug/mL) |
|
|
Term
| Labs for Valproate (depakote) |
|
Definition
| LFTs; CBC with platelet; (50-125 ug/mL) |
|
|
Term
|
Definition
| initial SCr, electrolytes, thyroid, CBC and preg. test; electrolytes and SCr Q 2weeks for two months, then 3-4 times yearly; (0.6-1.2 mEq/L) and (0.4-0.8 mEq/L) |
|
|
